On Monday, Jefferies made a positive shift in its stance on 10X Genomics (NASDAQ:TXG), upgrading the stock from Hold to Buy and setting a price target of $24.00. The change in rating reflects the firm’s confidence in the company’s prospects, particularly in the field of single cell genomics.
The upgrade is based on several factors that signal a strong outlook for 10X Genomics. Jefferies cited the company’s continued utility in critical research areas such as oncology, its superior technology compared to competitors, and a robust customer base in core laboratories. These core labs are less dependent on National Institutes of Health (NIH) funding, which adds to the company’s stability.
Furthermore, Jefferies believes there is potential for upside to the company’s 2025 financial projections due to the expected recovery in the single cell market and the introduction of new products.
While the firm is not making predictions about the company’s second-quarter performance, the upgrade is grounded in a long-term belief in the business’s strength and current valuation, which is approximately two times sales.
The analyst’s comments highlight the rationale behind the upgrade: “We upgrade TXG to Buy on conviction in single cell recovery given 1) continued utility in areas such as oncology research, 2) superior technology vs. competitors, 3) a large customer base of core labs, which limits dependency on NIH funding, and 4) upside to ’25 numbers due to a recovery in single cell and new products.”
Investors and market watchers will likely monitor 10X Genomics’ performance closely, especially in light of the positive outlook from Jefferies. The company’s efforts in advancing single cell genomics technology and its strategic position within the research community are key factors contributing to this optimistic assessment.
In other recent news, significant developments have been observed with 10X Genomics. JPMorgan (NYSE:) and Deutsche Bank (ETR:) have downgraded the company’s stock rating due to concerns over increased competition in the spatial and single-cell markets, as well as a challenging macroeconomic landscape.
In contrast, ARK ETFs have demonstrated strong interest in the company, purchasing hundreds of thousands of shares, indicating confidence in 10X Genomics’ long-term growth potential.
Stifel, a financial services company, has also adjusted its outlook on 10X Genomics, reducing the price target due to concerns about the company’s transition to its new GEM-X chemistry. However, overall expectations for consumable spending for the full year of 2024 remain relatively positive.
10X Genomics has also made strategic changes to its board with the appointment of Sarah A. Teichmann, who brings extensive academic and industry experience in genomics.
This appointment is expected to provide valuable insights to the company’s strategic direction. These developments highlight the dynamic investment strategies and evolving market conditions impacting 10X Genomics.
InvestingPro Insights
Following Jefferies’ upgrade of 10X Genomics (NASDAQ:TXG) to a Buy rating, a look at the company through the lens of InvestingPro data and tips provides additional context for investors. With a market capitalization of $2 billion, 10X Genomics holds a notable position in the biotech industry. According to InvestingPro data, the company’s revenue growth over the last twelve months as of Q1 2024 stands at a solid 16.64%, reflecting its strong foothold in the single cell genomics space. Furthermore, the gross profit margin during the same period is an impressive 64.62%, indicating efficient operations despite the company’s lack of profitability thus far.
Key InvestingPro Tips for 10X Genomics include the company’s substantial cash reserves compared to its debt, which provides financial flexibility. Additionally, while the stock has experienced significant volatility and a notable price decline over the past year, it is essential to recognize that the company’s liquid assets exceed its short-term obligations, suggesting a stable financial footing for near-term operations.
To gain deeper insights and access additional InvestingPro Tips for 10X Genomics, investors can visit https://www.investing.com/pro/TXG. There are currently six more tips available, which can provide further guidance on the company’s financial health and stock performance. For those interested in a comprehensive analysis, use the coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription at InvestingPro.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
